K2 Therapeutics Secures $50M Seed Funding and Appoints Former Legend Biotech CEO Dr. Ying Huang as Chief Executive Officer

VCBeat has learned exclusively that K2 Therapeutics (“K2”), a biotechnology company aiming to achieve global influence, announced today the appointment of Dr. Ying Huang as its Chief Executive Officer, along with securing a $50 million seed financing round from MPM BioImpact.

K2, established by MPM BioImpact in 2024, has been continuously exploring new models for biotech innovation by combining global asset sourcing with experienced drug development leadership to identify and advance high-potential first-in-class and best-in-class candidate drugs.

The proceeds from this round of financing have been used to support the continuous expansion of the company’s pipeline and to advance the various assets it has in-licensed globally.

Dr. Huang Ying stated:“K2 represents a highly compelling new model for biotech innovation and drug development, combining global asset sourcing with experienced development leadership. K2 holds a unique advantage in rapidly advancing differentiated drug candidates, with the potential to address a wide range of unmet medical needs. What excites me most is the opportunity here to converge complementary strengths from the global biotech ecosystem, integrating innovative science with world-class capabilities in drug development, regulatory affairs, and commercialization. I am eager to join K2 and help build a globally positioned and influential biotechnology company that delivers tangible benefits to patients worldwide.””

Dr. Huang Ying has over 20 years of industry experience, spanning biotechnology R&D, corporate strategy, capital markets, and business management.

Prior to joining K2, he served as Chief Executive Officer and a member of the Board of Directors at Legend Biotech, where he helped lead the global development and commercialization of innovative cell therapies, including CARVYKTI® (ciltacabtagene autoleucel). This product was among the first to achieve commercial success in the United States after originating from China, with annual sales exceeding $2 billion.

Under his leadership, Legend Biotech has gradually grown into a fully integrated global biopharmaceutical company with an end-to-end value chain spanning R&D, GMP manufacturing, and commercial operations, employing over 3,000 people.

Prior to joining Legend Biotech, Dr. Huang Ying served as the Head of Biotechnology Equity Research at Bank of America Merrill Lynch and was a top-tier biotechnology equity research analyst in the industry.

His career began in the field of pharmaceutical R&D. He holds a Ph.D. in Bioorganic Chemistry from Columbia University and previously studied at the Special Class for the Gifted Young of the University of Science and Technology of China, as well as at Columbia Business School.

Ansbert Gadicke, M.D., Chairman of K2 Therapeutics and Managing Partner of MPM BioImpact, stated:“Dr. Huang Ying is one of the few leaders in the biotechnology sector whose career spans the entire innovation value chain, with extensive experience ranging from scientific research and operational execution to capital management and corporate governance. During her tenure at Legend Biotech, Dr. Huang spearheaded one of the most impactful success stories in modern biotechnology, transforming an innovation originating in China into a globally approved blockbuster therapy, thereby reshaping industry perceptions regarding the sources of world-class innovation. We are delighted to have Dr. Huang at the helm of K2 Therapeutics, working together to build a biotechnology company capable of discovering exceptional science globally and advancing it into transformative medicines.””

Dr. Gadicke added, “For over 30 years, MPM BioImpact has remained steadfast in its simple yet unwavering belief that transformative science can change the course of human health. Along the way, we have partnered with exceptional entrepreneurs and scientists to build companies around breakthrough innovations and deliver important new medicines to patients. Today, groundbreaking scientific discoveries are emerging worldwide, creating unprecedented opportunities to improve and extend human life. K2 was founded precisely to unlock this potential—by identifying outstanding scientific innovations globally, combining them with deep expertise in drug development, and providing the resources necessary to translate innovation into tangible benefits for patients. This $50 million seed investment reflects our strong confidence in this vision, our endorsement of K2’s initial asset portfolio, and our determination to build a company capable of delivering significant breakthroughs for patients worldwide.””

K2 Therapeutics builds a diversified pipeline of innovative therapies by identifying high-potential projects globally and advancing them through focused drug development. Currently, the company’s pipeline comprises eight projects spanning multiple technological modalities, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), with assets ranging from preclinical development to clinical stages.

Dr. Frank Neumann, Chief Medical Officer of K2 Therapeutics, stated:“Dr. Huang Ying’s appointment marks a new chapter for K2 Therapeutics as it builds a global biotechnology company centered on scientific excellence. We have established a high-quality, differentiated portfolio of therapeutic programs, underpinned by rigorous scientific assessment and standardized development practices. Leveraging Dr. Huang’s proven leadership and the collective strength of our team, we are confident in advancing these programs efficiently while delivering significant value to patients and stakeholders.”

Looking ahead, K2 will continue to search for and evaluate innovative therapeutic opportunities globally, continuously expanding its product pipeline through prudent asset in-licensing, strategic capital allocation, and focused development execution.

K2 Therapeutics is a biotechnology company dedicated to achieving global impact, with the capability to identify and develop projects unrestricted by technological pathways or geographic boundaries. The company sources the most innovative assets worldwide and transforms them into superior medicines through rigorous development pathways led by an experienced drug development team. K2 Therapeutics aims to build a product pipeline focused on high-potential first-in-class and best-in-class projects, delivering tangible benefits to patients globally.

MPM BioImpact is a globally leading biotechnology investment firm with over 30 years of expertise in founding and investing in innovative companies, dedicated to delivering transformative therapies for patients. Its team of seasoned and focused investment professionals, entrepreneurs, advisors, and top-tier scientists is committed to translating scientific discoveries into breakthrough medicines and potential cures. The firm manages more than $3.5 billion in assets across early-stage venture capital funds, private/public market impact funds, and public equity funds.